Abstract | OBJECTIVE: METHODS: A total of 180 patients treated with risperidone-based (n=130) or clozapine-based (n=50) regimens were included in this study. Blood samples were analyzed for genotyping of the candidate genes and biochemical testing. Genotyping was performed by conducting a TaqMan real-time polymerase chain reaction-based analysis. RESULTS: The prevalence of hyperglycemia was higher in patients receiving clozapine (64.0%) than in those receiving risperidone (30.8%). Among the candidate genes, only the LEP rs7799039 polymorphism demonstrated a significant association with hyperglycemia (χ2=9.879, P=0.008) in patients treated with risperidone; patients with the AA genotype had the highest risk (41.1%), followed by those with AG (20.8%) and GG (0%) genotypes. Using the recessive genetic model (AA vs AG + GG), the odds ratio and 95% CI were 3.28 and 1.44 -7.50, respectively. None of the genes were associated with hyperglycemia in patients treated with clozapine. A binary logistic regression revealed that the LEP rs7799039 polymorphism demonstrated a significant association with hyperglycemia, independent of body-mass index (BMI) in patients receiving risperidone; the odds ratio (95% CI) was 3.188 (1.399-7.262), P=0.006. By contrast, none of the pharmacodynamic genetic factors, except for BMI, were significantly associated with hyperglycemia in patients receiving clozapine. CONCLUSION:
|
Authors | Apichaya Puangpetch, Pornpen Srisawasdi, Weerapon Unaharassamee, Napa Jiratjintana, Somlak Vanavanan, Suweejuk Punprasit, Chalitpon Na Nakorn, Chonlaphat Sukasem, Martin H Kroll |
Journal | Pharmacogenomics and personalized medicine
(Pharmgenomics Pers Med)
Vol. 12
Pg. 155-166
( 2019)
ISSN: 1178-7066 [Print] New Zealand |
PMID | 31496784
(Publication Type: Journal Article)
|